Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation

Department of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Nutrition Reviews (Impact Factor: 5.54). 03/2013; 71(3):180-8. DOI: 10.1111/nure.12011
Source: PubMed

ABSTRACT Coenzyme Q10 (CoQ10) is the only lipid-soluble antioxidant that animal cells synthesize de novo. It is found in cell membranes and is particularly well known for its role in the electron transport chain in mitochondrial membranes during aerobic cellular respiration. A deficiency in either its bioavailability or its biosynthesis can lead to one of several disease states. Primary deficiency has been well described and results from mutations in genes involved in CoQ10 biosynthesis. Secondary deficiency may be linked to hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), which are used for the treatment of hypercholesterolemia. Dietary contributions of CoQ10 are very small, but supplementation is effective in increasing plasma CoQ10 levels. It has been clearly demonstrated that treatment with CoQ10 is effective in numerous disorders and deficiency states and that supplementation has a favorable outcome. However, CoQ10 is not routinely prescribed in clinical practice. This review explores primary as well as statin-induced secondary deficiency and provides an overview of the benefits of CoQ10 supplementation.

Download full-text


Available from: Michael S. Pepper, Feb 19, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: L-lactate formation occurs via the reduction of pyruvate catalyzed by lactate dehydrogenase. L-lactate removal takes place via its oxidation into pyruvate, which may be oxidized or converted into glucose. Pyruvate oxidation involves the cooperative effort of pyruvate dehydrogenase, the tricarboxylic acid cycle, and the mitochondrial respiratory chain. Enzymes of the gluconeogenesis pathway sequentially convert pyruvate into glucose. In addition, pyruvate may undergo reversible transamination to alanine by alanine aminotransferase. Enzymes involved in L-lactate metabolism are crucial to diabetes pathophysiology and therapy. Elevated plasma alanine aminotransferase concentration has been associated with insulin resistance. Polymorphisms in the G6PC2 gene have been associated with fasting glucose concentration and insulin secretion. In diabetes patients, pyruvate dehydrogenase is down-regulated and the activity of pyruvate carboxylase is diminished in the pancreatic islets. Inhibitors of fructose 1,6-bisphosphatase are being investigated as potential therapy for type 2 diabetes. In addition, enzymes implicated in L-lactate metabolism have revealed to be important in cancer cell homeostasis. Many human tumors have higher LDH5 levels than normal tissues. The LDHC gene is expressed in a broad range of tumors. The activation of PDH is a potential mediator in the body response that protects against cancer and PDH activation has been observed to reduce glioblastoma growth. The expression of PDK1 may serve as a biomarker of poor prognosis in gastric cancer. Mitochondrial DNA mutations have been detected in a number of human cancers. Genes encoding succinate dehydrogenase have tumor suppressor functions and consequently mutations in these genes may cause a variety of tumors.
    Mitochondrion 09/2013; 13(6). DOI:10.1016/j.mito.2013.08.011 · 3.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The autosomal-recessive cerebellar ataxias (ARCA) are a clinically and genetically heterogeneous group of neurodegenerative disorders. The large number of ARCA genes leads to delay and difficulties obtaining an exact diagnosis in many patients and families. Ubiquinone (CoQ10) deficiency is one of the potentially treatable causes of ARCAs as some patients respond to CoQ10 supplementation. The AarF domain containing kinase 3 gene (ADCK3) is one of several genes associated with CoQ10 deficiency. ADCK3 encodes a mitochondrial protein which functions as an electron-transfer membrane protein complex in the mitochondrial respiratory chain (MRC). We report two siblings from a consanguineous Pakistani family who presented with cerebellar ataxia and severe myoclonus from adolescence. Whole exome sequencing and biochemical assessment of fibroblasts were performed in the index patient. A novel homozygous frameshift mutation in ADCK3 (p.Ser616Leufs*114), was identified in both siblings. This frameshift mutation results in the loss of the stop codon, extending the coding protein by 81 amino acids. Significant CoQ10 deficiency and reduced MRC enzyme activities in the index patient's fibroblasts suggested that the mutant protein may reduce the efficiency of mitochondrial electron transfer. CoQ10 supplementation was initiated following these genetic and biochemical analyses. She gained substantial improvement in myoclonic movements, ataxic gait and dysarthric speech after treatment. This study highlights the importance of diagnosing ADCK3 mutations and the potential benefit of treatment for patients. The identification of this new mutation broadens the phenotypic spectrum associated with ADCK3 mutations and provides further understanding of their pathogenic mechanism.
    Journal of neurology, neurosurgery, and psychiatry 11/2013; 85(5). DOI:10.1136/jnnp-2013-306483 · 5.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Nitrogen-bisphosphonates (N-BP) are the most widely used drugs for bone fragility disorders. Long-term or high dose N-BP use is associated with unusual serious side effects such as osteonecrosis of the jaw, musculoskeletal pain and atypical fractures of long bones. It has escaped notice that the pathway N-BP block is central for the endogenous synthesis of coenzyme Q10, an integral enzyme of the mitochondrial respiratory chain and important lipid soluble antioxidant. Our objective was to assess the coenzyme Q10 and antioxidant status in relation to N-BP exposure in women with postmenopausal osteoporosis. Methods: 71 postmenopausal women (73.5±5.5 yrs) with osteoporosis and no other malignancy were included in this cross-sectional study. 17 were treatment naive, 27 on oral, and 27 on intravenous (IV) N-BP. Results: Vitamin E gamma-tocopherol levels (μmol/mL) were significantly reduced in N-BP users (H(2)=18.5, p=0.02 oral; H(2)=25.2, p<0.001 IV; mean rank comparisons following Kruskal-Wallis test). Length of time (days) of N-BP exposure, but not age, was inversely associated with the coenzyme Q10/cholesterol ratio (μmol/mol) (β=-0.27, p=0.025), which was particularly low for those on IV N-BP (mean difference = -35.0±16.9, 95% CI = -65.2 to -4.9, p=0.02). Conclusion: The degree of N-BP exposure appears related to compromised coenzyme Q10 status and vitamin E gamma-tocopherol levels in postmenopausal women with osteoporosis. This phenomenon may link to certain adverse N-BP-associated effects. Confirmation of this would suggest therapeutic supplementation could prevent or reverse certain complications of long-term N-BP therapy for at risk individuals.
    The Journal of Clinical Endocrinology and Metabolism 01/2014; 99(4):jc20133648. DOI:10.1210/jc.2013-3648 · 6.31 Impact Factor